139 related articles for article (PubMed ID: 37680811)
1. Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain.
Yan J; Xie ZZ; Ma N; Zheng MD; Qiao TT; Wang Y
Pak J Med Sci; 2023; 39(5):1492-1495. PubMed ID: 37680811
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief).
Inoue S; Saito Y; Tsuneto S; Aruga E; Ide A; Kakurai Y
J Pain Res; 2017; 10():1953-1962. PubMed ID: 28860850
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: A multicenter, open-label, randomized controlled trial (SOCIAL).
Pan H; Shen P; Shu Q; Lu L; Qian S; Zhou Y; Han F; Guo Q; Yang Z; Pan J; Xu Q; Zhang P; Wang K
Medicine (Baltimore); 2019 Jun; 98(24):e15505. PubMed ID: 31192908
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients.
Inoue S; Saito Y; Tsuneto S; Aruga E; Takahashi H; Uemori M
Jpn J Clin Oncol; 2018 Jun; 48(6):542-547. PubMed ID: 29659913
[TBL] [Abstract][Full Text] [Related]
5. A 12-hour rapid titration method for cancer pain: a randomized, controlled, open-label study.
Liang J; Chen L; Yang S; Zhang H; Li L; Chen Z; Zhang S; Xian H; Tang Y; Deng Y; Feng W
Ann Palliat Med; 2021 Jan; 10(1):88-96. PubMed ID: 33474955
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
[TBL] [Abstract][Full Text] [Related]
7. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
J Opioid Manag; 2006; 2(3):155-66. PubMed ID: 17319449
[TBL] [Abstract][Full Text] [Related]
8. Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain.
Xiao Y; Liu J; Huang XE; Ca LH; Ma YM; Wei W; Zhang RX; Huang XH; Chang J; Wu YJ
Asian Pac J Cancer Prev; 2014; 15(23):10445-9. PubMed ID: 25556490
[TBL] [Abstract][Full Text] [Related]
9. [Effects of sustained release morphine hydrochloride tablets in management of cancer pain: a survey of 567 patients].
Yu SY; Qiu H; Ma ZS; Chen J; Zhang Y; Chen LZ; Wang DL; Ma ZY
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):450-5. PubMed ID: 15061959
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
J Opioid Manag; 2006; 2(6):325-8, 331-3. PubMed ID: 17326594
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy comparison between morphine sulfate controlled-released tablet and morphine hydrochloride sustained-released tablet in treating cancer pain].
Yao WX; Zhou H; Wang LY; Wei Y; Liu XY
Ai Zheng; 2007 Dec; 26(12):1357-9. PubMed ID: 18076801
[TBL] [Abstract][Full Text] [Related]
13. [Clinical observation of filiform fire needling on moderate and severe pain in advanced cancer].
Gao X; Zhang SN
Zhongguo Zhen Jiu; 2020 Jun; 40(6):601-4. PubMed ID: 32538009
[TBL] [Abstract][Full Text] [Related]
14. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
15. Oxycodone versus morphine for cancer pain titration: A systematic review and pharmacoeconomic evaluation.
Zhou J; Wang Y; Jiang G
PLoS One; 2020; 15(4):e0231763. PubMed ID: 32302346
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of the Clinical Effectiveness Between Low-Dose Strong Opioids and Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Mild Cancer Pain: A Randomized Trial.
Liu MZ; Ma J; Li JD; Sun J; Zhou H; Guan S; Han Y; Zhang X; Bian JL
J Pain Res; 2021; 14():3411-3419. PubMed ID: 34754234
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study.
Feng W; Wang Y; Ran F; Mao Y; Zhang H; Wang Q; Lin W; Wang Z; Hu J; Liao W; Zhang T; Chu Q; Xiong W; Yi T; Yi J; Ma S; Sun Y; Meng L; Liu C; Zhou S; Zheng D; Wang S; Lin H; Fang W; Li J; Wu M
Front Med (Lausanne); 2022; 9():918468. PubMed ID: 36267618
[TBL] [Abstract][Full Text] [Related]
18. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol.
Samolsky Dekel BG; Tomasi M; Vasarri A; Gori A; Adversi M; Castagnoli A; Di Nino G; Melotti RM
J Opioid Manag; 2014; 10(1):29-38. PubMed ID: 24604567
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet.
Lux EA; Janecki M; Maritz MA
Curr Med Res Opin; 2014 Nov; 30(11):2365-75. PubMed ID: 25050592
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of efficacy and safety of sustained release oxycodone hydrochloride rectal administration for moderate to severe pain.
Hou XB; Chen DD; Cheng TF; Wang D; Dai XJ; Wang Y; Cui BX; Wang YY; Xu H; Chen HZ
PLoS One; 2022; 17(6):e0266754. PubMed ID: 35759471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
